What are the Clinical and Research Priorities in Cholangiocarcinoma?

Prof Shahid A Khan

Consultant Hepatologist
Imperial College London

Cholangiocarcinoma UK Annual Conference
14th November 2018
Nottingham

CLINICAL & RESEARCH PRIORITIES IN CHOLANGIOCARCINOMA

Cholangiocarcinoma UK Committee - 2019

Clinical

1. Dedicated regional centres of multidisciplinary expertise

2. Access to molecular profiling for all UK patients at diagnosis to aid systemic therapy choices

3. Access to trials for all suitable patients

4. Developing the role of local regional therapies including ablation, embolization and radiation therapy

5. Evaluating the role of radiotherapy

6. Defining a national standard for minimal data collection at MDTs in reference to CCA

7. Reassessing a role for liver transplantation in CCA

8. The role of immunotherapy

9. Defining surveillance strategies for CC in PSC

10. Defining the role of aspirin in the prevention and treatment of CCA

11. Ensure adequate training is in place for the next generation of HPB Specialists

12. Development of novel therapeutics

13. Identification of predictive biomarkers/tool for personalised medicine

shahid.khan@imperial.ac.uk

CHOLANGIOCARCINOMA
UK

BASL
British Association for the Study of the Liver

CLINICAL & RESEARCH PRIORITIES IN CHOLANGIOCARCINOMA

Cholangiocarcinoma UK Committee - 2019

Basic / Translational Research

1. Monitoring of patterns of rising incidence of CCA and other HPB cancers

2. Understanding the impact of clinical risk factors (including NAFLD & other causes of liver disease, toxins etc.)

3. Investigating areas of high incidence

4. Combining morphological and molecular descriptive profiling

5. Validation studies of diagnostic and prognostic biomarkers

6. Applying radiomics and Artificial Intelligence to develop diagnostic/prognostic algorithms

7. Standardised guidelines for collection of tissue, biofluids and clinical data

8. National platforms to facilitate access to tissue and bio-samples from patients enrolled in trials

9. Development of experimental models

10. Characterization of animal models

11. Increase understanding of the tumour microenvironment including innate and adaptive immunity

shahid.khan@imperial.ac.uk

shahid.khan@imperial.ac.uk